Quality care is our passion

“ CFM is providing new standards in tissue repair. ”



CFM is continuously investigating new drug compounds to ensure cutting edge therapies in trauma care at great length.



In order to expand its field of target indications, CFM tests new compounds in collaboration with leading international research groups.


Heavy metals are usually considered toxic. Vanadium is a heavy metal of the transition elements and has multiple oxidation states. Oxidation states of vanadium include +1, +2, +3, +4 and +5.

The toxicity of vanadium depends on its physico-chemical state; particularly on its valence state, solubility and whether it’s part of an inorganic or organic molecule. Vanadate (5+) and especially Vanadyl (4+) organic vanadium compounds have shown to be much safer than inorganic vanadium salts and don’t cause any gastrointestinal discomfort, hepatic or renal toxicity.


Vanadium itself is present in a variety of foods that we commonly eat like skim milk, lobster, vegetable oils, many vegetables, grains and cereals. Organic forms of vanadium, as opposed to the inorganic sulfate salt of vanadium, are recognized as safer, better absorbed, and able to deliver a therapeutic effect up to 50% greater than the inorganic forms.

To provide vanadium in a form that is best able to deliver the desired biological effects, numerous organic complexes of vanadium have been developed including bis(maltolato)oxovanadium (BMOV), bis(cysteinamide N-octyl)oxovanadium known as Naglivan, bis(pyrrolidine-N-carbodithioato)oxovanadium, vanadyl-cysteine methyl ester, and bis-glycinato oxovanadium (BGOV)30.


VANADIS® (BMOV), CFM’s lead compound has shown to be safe and effective and has well-understood mechanisms of action. It has been on the market for many years as a food supplement, and is intensively being studied by many research groups because of its known safety profile and potential as a drug in several indications.

VANADIS® has to be applied as a single or double dose. Single or double dose treatment is considered to be much safer in use than repeated dose because of the absence of long-term risks.

Blood Glucose Control

Clinical trials in humans (with vanadium compounds like Bis(ethylmaltolato)oxovanadium (BEOV),a BMOV analog, with the same pharmacological and activity profile, that have proven to be effective in Type II diabetes) have shown blood glucose lowering effects due to insulin enhancing and IGF (insulin like growth factor) up regulation.

The clinical trial results confirm an important mechanism of action previously shown in many preclinical studies, including the safety of the compound. This is also the basis of the many mechanisms involved in wound repair, which also have been shown to be addressed by vanadate (the active compound in BMOV) in many preclinical studies.

Therefore, CFM expects that VANADIS® will show significant wound repair in patients in the targeted indications.

Proven in studies

The mechanisms of action have been proven in studies in various indications and each of them is confirming the underlying shared pathways in ischemia/ reperfusion injury and tissue repair: VANADIS® is a potent PTEN inhibitor and PI3K/Akt and ERK activator which are well understood regulators of cell survival and apoptosis.

Recent studies show that these are key in preventing heart damage after an ischemic insult, coronary angiogenesis, hypertrophy and heart failure following hypertension in postmenopausal women.

It also protects against neuronal death in ischemic stroke, protects kidneys against damage and accelerates nerve repair. Next to that VANADIS® has insulin mimicking properties, which are especially beneficial in trauma settings, thanks to the ability to maintain normoglycaemia in critically ill patients.

This means that the detrimental effects of stress induced acute hyperglycemia can be reduced or prevented.